Ben Khelil M, Fredon M, Adib N, Bouard A, Perchaud M, Abdeljaoued S, Mantion CF, Asgarov K, Guillaume P, Spehner L, Seffar E, Labesse M, Vienot A, Mougey V, Gonçalves-Venturelli M, Bobisse S, Harari A, Jandus C, Garnache-Ottou F, Binda D, Adotévi O, Godet Y, Kroemer M, Borg C, Loyon R

Cancer Immunol Res. 2025 10 20;:

Beneficial effect of resveratrol on T cell oxidative metabolism and anti-tumor function is conditioned by prior T cell history.

Mercier-Letondal P, Marton C, Royer B, Peixoto P, Dehecq B, Adotévi O, Galaine J, Godet Y

Mol Ther Methods Clin Dev. 2025 09 11;33(3):101553

Venetoclax in the Therapeutic Strategy for BPDCN Management.

Poussard M, Fredon M, Belakri I, Biichle S, Renosi F, Seffar E, Boichut M, Boidot R, Bôle-Richard E, Bonnefoy F, Kroemer M, Bonnot-Perrin S, Saas P, Adotévi O, Garnache-Ottou F, Angelot-Delettre F

EJHaem. 2025 08;6(4):e70070

Engineered CD4 TCR T cells with conserved high-affinity TCRs targeting NY-ESO-1 for advanced cellular therapies in cancer.

Saillard M, Cenerenti M, Reichenbach P, Guillaume P, Su Z, Hafezi M, Schmidt J, Cesbron J, Genolet R, Queiroz L, Racle J, Villard J, Renella R, Michielin O, Zoete V, Rivals JP, Irving M, Speiser DE, Harari A, Gfeller D, Adotevi O, Ceppi F, Coukos G, Romero P, Jandus C

Sci Adv. 2025 06 27;11(26):eadu5754

UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunity.

Laheurte C, Boullerot L, Ndao B, Malfroy M, Queiroz L, Guillaume P, Loyon R, Seffar E, Gravelin E, Renaudin A, Jacquin M, Meurisse A, Vernerey D, Ghiringhelli F, Godet Y, Genoley R, Jandus C, Borg C, Adotévi O

Cell Rep Med. 2025 06 17;:102196

Deciphering human endogenous retrovirus expression in colorectal cancers: exploratory analysis regarding prognostic value in liver metastases.

Viot J, Loyon R, Adib N, Laurent-Puig P, de Reyniès A, André F, Monnien F, André T, Svrcek M, Turpin A, Selmani Z, Arnould L, Guyard L, Gilbert N, Boureux A, Adotevi O, Vienot A, Abdeljaoued S, Vernerey D, Borg C, Gautheret D

EBioMedicine. 2025 05 16;116:105727

Characterization of the aryl hydrocarbon receptor as a potential candidate to improve cancer T cell therapies.

De Castro V, Abdellaoui O, Dehecq B, Ndao B, Mercier-Letondal P, Dauvé A, Garnache-Ottou F, Adotévi O, Loyon R, Godet Y

Cancer Immunol Immunother. 2025 05 13;74(7):200

New leads to enhance tagraxofusp efficacy in pDC-AML.

Boichut M, Poussard M, Roussel X, Belakri I, Biichlé S, Fredon M, Renosi F, Boidot R, Adotevi O, Brooks C, Garnache-Ottou F, Angelot Delettre F

Blood Neoplasia. 2025 05;2(2):100066

TIE-2 expressing monocytic myeloid-derived suppressor cells are involved in resistance to anti-PD-1 therapy mediated by angiopoietin 2 in melanoma patients.

Marguier A, Mathiot J, NDao B, Wespiser M, Pereira V, Lecoester B, Boullerot L, Malfroy M, Laheurte C, Aubin F, Adotevi O, Nardin C

J Invest Dermatol. 2025 03 18;:

Mimicry-based strategy between human and commensal antigens for the development of a new family of immune therapies for cancer.

Talpin A, Maia A, Carpier JM, Kulakowski G, Aubergeon L, Kervevan J, Gaal C, Strozzi F, Billerey C, Amable L, Mersceman T, Garnier A, Oliveira C, Calderon C, Bachrouche D, Ventujol C, Bernard L, Manteau A, Martinez J, Bonnet M, Noguerol J, Laviolette K, Boullerot L, Malfroy M, Chevalier G, Adotevi O, Joffre O, Idbaih A, Vieito M, Ghiringhelli F, Stradella A, Tabatabai G, Burger MC, Mildenberger I, Herrlinger U, Reardon DA, Wick W, Gouttefangeas C, Bonny C, Chene L, Gamelas Magalhaes J

J Immunother Cancer. 2025 02 20;13(2):

Enzyme-linked ImmunoSpot (ELISpot) assay to quantify peptide-specific IFN-γ production by splenocytes in a mouse tumor model after radiation therapy.

Lecoester B, Xie Y, Marguier A, Boulerot L, Malfroy M, Adotévi O, Boustani J

Methods Cell Biol. 2024 09 5;189:41-54

Impact of scFv on functionality and safety of third generation CD123 CAR T cells.

Fredon M, Poussard M, Biichlé S, Bonnefoy F, Mantion CF, Seffar E, Renosi F, Bôle-Richard E, Boidot R, Chevrier S, Anna F, Loustau M, Caumartin J, Gonçalves-Venturelli M, Robinet E, Saas P, Deconinck E, Daguindau E, Roussel X, Godet Y, Adotévi O, Angelot-Delettre F, Galaine J, Garnache-Ottou F

Cancer Immunol Res. 2024 05 31;:

Targeting two radiation-induced immunosuppressive pathways to improve the efficacy of normofractionated radiation therapy in a preclinical colorectal cancer model.

Boustani J, Lecoester B, Baude J, Latour C, Limagne E, Ladjohoulou R, Morgand V, Froidurot L, Ghiringhelli F, Truc G, Adotévi O, Mirjolet C

Int J Radiat Biol. 2024 03 20;:1-10

Characterization of atypical T cells generated during expansion process for T cell-based adoptive immunotherapy.

Mercier-Letondal P, Kumar A, Marton C, Bonnefoy F, Fredon M, Boullerot L, Dehecq B, Adotévi O, Godet Y, Galaine J

Front Immunol. 2024 03 13;15:1202017

THBS1 myeloid cells expand in SLD hepatocellular carcinoma and contribute to immunosuppression and unfavorable prognosis through TREM1.

Giraud J, Chalopin D, Ramel E, Boyer T, Zouine A, Derieppe MA, Larmonier N, Adotevi O, Le Bail B, Blanc JF, Laurent C, Chiche L, Derive M, Nikolski M, Saleh M

Cell Rep. 2024 02 12;:113773

Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trial.

Spehner L, Orillard E, Falcoz A, Lepiller Q, Bouard A, Almotlak H, Kim S, Curtit E, Meynard G, Jary M, Nardin C, Asgarov K, Abdeljaoued S, Chartral U, Mougey V, Ben Khelil M, Lopez M, Loyon R, Vernerey D, Adotevi O, Borg C, Mansi L, Kroemer M

BMJ Oncol. 2023 12 14;2(1):e000054

Use of cancer vaccine after immunotherapy failure: a promising strategy for advanced NSCLC patients with secondary resistance to checkpoint inhibitors.

Adotevi O

Ann Oncol. 2023 08 17;:

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial.

Thibaudin M, Fumet JD, Chibaudel B, Bennouna J, Borg C, Martin-Babau J, Cohen R, Fonck M, Taieb J, Limagne E, Blanc J, Ballot E, Hampe L, Bon M, Daumoine S, Peroz M, Mananet H, Derangère V, Boidot R, Michaud HA, Laheurte C, Adotevi O, Bertaut A, Truntzer C, Ghiringhelli F

Nat Med. 2023 08 10;:

Durable response of lung carcinoma patients to EGFR tyrosine kinase inhibitors is determined by germline polymorphisms in some immune-related genes.

Dalens L, Niogret J, Richard C, Chevrier S, Foucher P, Coudert B, Lagrange A, Favier L, Westeel V, Kim S, Adotevi O, Chapusot C, Martin L, Arnould L, Kaderbhai CG, Boidot R

Mol Cancer. 2023 07 29;22(1):120

Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).

Vienot A, Jacquin M, Rebucci-Peixoto M, Pureur D, Ghiringhelli F, Assenat E, Hammel P, Rosmorduc O, Stouvenot M, Allaire M, Bouattour M, Regnault H, Fratte S, Raymond E, Soularue E, Husson-Wetzel S, Di Martino V, Muller A, Clairet AL, Fagnoni-Legat C, Adotevi O, Meurisse A, Vernerey D, Borg C

BMC Cancer. 2023 07 29;23(1):710

Production of functional plasmacytoid dendritic cells-targeted CAR-T cells from patients with immune-mediated inflammatory diseases.

Caël B, Bôle-Richard E, Galaine J, Adotevi O, Garnache-Ottou F, Aubin F

Br J Dermatol. 2023 04 6;:

Development of a new heparan sulfate proteoglycan (HSPG) chromolith LC column to study the pH dependence binding of peptide vaccines to HSPG and role of human serum albumin on its binding.

André C, Lethier L, Adotevi O, Guillaume YC

Anal Methods. 2023 02 22;:

Response to Chemoimmunotherapy Is Associated With Expansion of Systemic Antitumor CD4+ Th1 Response in Metastatic Non-Small Cell Lung Cancer.

Wespiser M, Marguier A, Lecoester B, Richard T, Boullerot L, Malfroy M, Kumar A, Laheurte C, Adotévi O

J Immunother. 2023 02 20;:

Chemotherapy to potentiate the radiation-induced immune response.

Lecoester B, Wespiser M, Marguier A, Mirjolet C, Boustani J, Adotévi O

Int Rev Cell Mol Biol. 2023 02 11;376:143-173

Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based Vaccine in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study.

Adotévi O, Vernerey D, Jacoulet P, Meurisse A, Laheurte C, Almotlak H, Jacquin M, Kaulek V, Boullerot L, Malfroy M, Orillard E, Eberst G, Lagrange A, Favier L, Gainet-Brun M, Doucet L, Teixeira L, Ghrieb Z, Clairet AL, Guillaume Y, Kroemer M, Hocquet D, Moltenis M, Limat S, Quoix E, Mascaux C, Debieuvre D, Fagnoni-Legat C, Borg C, Westeel V

J Clin Oncol. 2022 09 7;:JCO2200096

Plasma CD27, a surrogate of the intratumoral CD27-CD70 interaction, correlates with immunotherapy resistance in renal cell carcinoma.

Benhamouda N, Sam I, Epaillard N, Gey A, Phan L, Pham HP, Gruel N, Saldmann A, Pineau J, Hasan M, Quiniou V, Nevoret C, Verkarre V, Libri V, Mella S, Granier C, Broudin C, Ravel P, De Guillebon E, Mauge L, Helley D, Jabla B, Chaput N, Albiges L, Katsahian S, Adam J, Mejean A, Adotevi O, Vano YA, Oudard S, Tartour E

Clin Cancer Res. 2022 09 6;:

The ATG8 Family Proteins GABARAP and GABARAPL1 Target Antigen to Dendritic Cells to Prime CD4 and CD8 T Cells.

Fonderflick L, Baudu T, Adotévi O, Guittaut M, Adami P, Delage-Mourroux R

Cells. 2022 09 6;11(18):

Interplay between plasmacytoid dendritic cells and tumor-specific T cells in peripheral blood influences long-term survival in non-small cell lung carcinoma.

Laheurte C, Seffar E, Gravelin E, Lecuelle J, Renaudin A, Boullerot L, Malfroy M, Marguier A, Lecoester B, Gaugler B, Saas P, Truntzer C, Ghiringhelli F, Adotevi O

Cancer Immunol Immunother. 2022 08 21;:

TIE-2 Signaling Activation by Angiopoietin 2 On Myeloid-Derived Suppressor Cells Promotes Melanoma-Specific T-cell Inhibition.

Marguier A, Laheurte C, Lecoester B, Malfroy M, Boullerot L, Renaudin A, Seffar E, Kumar A, Nardin C, Aubin F, Adotevi O

Front Immunol. 2022 07 22;13:932298

A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 T1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study.

Rebucci-Peixoto M, Vienot A, Adotevi O, Jacquin M, Ghiringhelli F, de la Fouchardière C, You B, Maurina T, Kalbacher E, Bazan F, Meynard G, Clairet AL, Fagnoni-Legat C, Spehner L, Bouard A, Vernerey D, Meurisse A, Kim S, Borg C, Mansi L

Front Oncol. 2022 07 19;12:957580

Umbilical Cord Blood as a Source of Less Differentiated T Cells to Produce CD123 CAR-T Cells.

Caël B, Galaine J, Bardey I, Marton C, Fredon M, Biichle S, Poussard M, Godet Y, Angelot-Delettre F, Barisien C, Bésiers C, Adotevi O, Pouthier F, Garnache-Ottou F, Bôle-Richard E

Cancers (Basel). 2022 06 28;14(13):

Prognostic value of CD4+ T lymphopenia in non-small cell lung Cancer.

Eberst G, Vernerey D, Laheurte C, Meurisse A, Kaulek V, Cuche L, Jacoulet P, Almotlak H, Lahourcade J, Gainet-Brun M, Fabre E, Le Pimpec-Barthes F, Adotevi O, Westeel V

BMC Cancer. 2022 05 11;22(1):529

c-Maf enforces cytokine production and promotes memory-like responses in mouse and human type 2 innate lymphoid cells.

Trabanelli S, Ercolano G, Wyss T, Gomez-Cadena A, Falquet M, Cropp D, Imbratta C, Leblond MM, Salvestrini V, Curti A, Adotevi O, Jandus C, Verdeil G

EMBO J. 2022 Apr 25;:e109300

Harnessing Antitumor CD4 T Cells for Cancer Immunotherapy.

Ben Khelil M, Godet Y, Abdeljaoued S, Borg C, Adotévi O, Loyon R

Cancers (Basel). 2022 Jan 5;14(1):

Human Monocyte-Derived Suppressor Cell Supernatant Induces Immunoregulatory Effects and Mitigates xenoGvHD.

Gérard C, Thébault M, Lamarthée B, Genet C, Cattin F, Brazdova A, Janikashvili N, Cladière C, Ciudad M, Ouandji S, Ghesquière T, Greigert H, Tinel C, Adotevi O, Saas P, Samson M, Audia S, Bonnotte B

Front Immunol. 2022 ;13:827712

The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors.

Kroemer M, Boullerot L, Ramseyer M, Spehner L, Barisien C, Gravelin E, Renaudin A, Cognasse F, Gallian P, Hermine O, Lacombe K, Tiberghien P, Adotévi O

Front Public Health. 2022 ;10:816848

Homeostatic cytokines tune naivety and stemness of cord blood-derived transgenic T cells.

Marton C, Mercier-Letondal P, Loyon R, Adotévi O, Borg C, Galaine J, Godet Y

Cancer Gene Ther. 2021 Oct 13;:

Anti-PD-1/Anti-PD-L1 Drugs and Radiation Therapy: Combinations and Optimization Strategies.

Boustani J, Lecoester B, Baude J, Latour C, Adotevi O, Mirjolet C, Truc G

Cancers (Basel). 2021 Sep 29;13(19):

Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies.

Malard F, Gaugler B, Gozlan J, Bouquet L, Fofana D, Siblany L, Eshagh D, Adotevi O, Laheurte C, Ricard L, Dulery R, Stocker N, van de Wyngaert Z, Genthon A, Banet A, Memoli M, Ikhlef S, Sestilli S, Vekhof A, Brissot E, Marjanovic Z, Chantran Y, Cuervo N, Ballot E, Morand-Joubert L, Mohty M

Blood Cancer J. 2021 08 10;11(8):142

Naturally occurring Telomerase-specific CD4 T cell Immunity in Melanoma.

Nardin C, Laheurte C, Puzenat E, Boullerot L, Ramseyer M, Marguier A, Jacquin M, Godet Y, Aubin F, Adotevi O

J Invest Dermatol. 2021 Aug 2;:

Inflammatory and immunological profile in COPD secondary to organic dust exposure.

Keddache S, Laheurte C, Boullerot L, Laurent L, Dalphin JC, Adotevi O, Soumagne T

Clin Immunol. 2021 Jul 16;:108798

Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy.

Lauret Marie Joseph E, Kirilovsky A, Lecoester B, El Sissy C, Boullerot L, Rangan L, Marguier A, Tochet F, Dosset M, Boustani J, Ravel P, Boidot R, Spehner L, Haicheur-Adjouri N, Marliot F, Pallandre JR, Bonnefoy F, Scripcariu V, Van den Eynde M, Cornillot E, Mirjolet C, Pages F, Adotevi O

J Immunother Cancer. 2021 Jul;9(7):

Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood.

Boustani J, Joseph ELM, Martin E, Benhmida S, Lecoester B, Tochet F, Mirjolet C, Chevalier C, Thibouw D, Vulquin N, Servagi S, Sun X, Adotévi O

BMC Immunol. 2021 Jun 18;22(1):38

Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients.

Mansi L, Spehner L, Daguindau E, Bouiller K, Almotlak H, Stein U, Bouard A, Kim S, Klajer E, Jary M, Meynard G, Vienot A, Nardin C, Bazan F, Lepiller Q, Westeel V, Adotévi O, Borg C, Kroemer M

Eur J Cancer. 2021 Mar 26;150:1-9

Polyploid giant cancer cells, stemness and epithelial-mesenchymal plasticity elicited by human cytomegalovirus.

Nehme Z, Pasquereau S, Haidar Ahmad S, Coaquette A, Molimard C, Monnien F, Algros MP, Adotevi O, Diab Assaf M, Feugeas JP, Herbein G

Oncogene. 2021 Mar 25;:

Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis.

Renosi F, Roggy A, Giguelay A, Soret L, Viailly PJ, Cheok M, Biichle S, Angelot-Delettre F, Asnafi V, Macintyre E, Geffroy S, Callanan M, Petrella T, Deconinck E, Daguindau E, Harrivel V, Bouyer S, Salaun V, Saussoy P, Feuillard J, Fuseau P, Saas P, Adotévi O, Jardin F, Ferrand C, Preudhomme C, Colinge J, Roumier C, Garnache-Ottou F

Blood Adv. 2021 Mar 9;5(5):1540-1551

First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G.

Anna F, Bole-Richard E, LeMaoult J, Escande M, Lecomte M, Certoux JM, Souque P, Garnache F, Adotevi O, Langlade-Demoyen P, Loustau M, Caumartin J

J Immunother Cancer. 2021 Mar;9(3):

BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR-T cell cytotoxicity.

Poussard M, Philippe L, Fredon M, Bôle-Richard E, Biichle S, Renosi F, Perrin S, Kroemer M, Limat S, Bonnefoy F, Daguindau E, Deconinck E, Gruson B, Saas P, Adotévi O, Garnache-Ottou F, Angelot-Delettre F

EJHaem. 2021 02;2(1):125-130

Feasibility of health-related quality of life (HRQoL) assessment for cancer patients using electronic patient-reported outcome (ePRO) in daily clinical practice.

Mouillet G, Falcoz A, Fritzsch J, Almotlak H, Jacoulet P, Pivot X, Villanueva C, Mansi L, Kim S, Curtit E, Meneveau N, Adotevi O, Jary M, Eberst G, Vienot A, Calcagno F, Pozet A, Djoumakh O, Borg C, Westeel V, Anota A, Paget-Bailly S

Qual Life Res. 2021 Jan 2;:

Epigenetic Reprogramming of CD4 Helper T Cells as a Strategy to Improve Anticancer Immunotherapy.

Renaude E, Kroemer M, Borg C, Peixoto P, Hervouet E, Loyon R, Adotévi O

Front Immunol. 2021 ;12:669992

Pro-Resolving Factor Administration Limits Cancer Progression by Enhancing Immune Response Against Cancer Cells.

Wetzel A, Bonnefoy F, Chagué C, Vetter M, Couturier M, Baffert B, Adotévi O, Saas P, Perruche S

Front Immunol. 2021 ;12:812171

Investigation of the prognostic value of CD4 T cell subsets expanded from tumor-infiltrating lymphocytes of colorectal cancer liver metastases.

Kroemer M, Turco C, Spehner L, Viot J, Idirène I, Bouard A, Renaude E, Deschamps M, Godet Y, Adotévi O, Limat S, Heyd B, Jary M, Loyon R, Borg C

J Immunother Cancer. 2020 Nov;8(2):

PD-1 and TIGIT coexpression identifies a circulating CD8 T cell subset predictive of response to anti-PD-1 therapy.

Simon S, Voillet V, Vignard V, Wu Z, Dabrowski C, Jouand N, Beauvais T, Khammari A, Braudeau C, Josien R, Adotevi O, Laheurte C, Aubin F, Nardin C, Rulli S, Gottardo R, Ramchurren N, Cheever M, Fling SP, Church CD, Nghiem P, Dreno B, Riddell SR, Labarriere N

J Immunother Cancer. 2020 Nov;8(2):

Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape.

Zalmaï L, Viailly PJ, Biichle S, Cheok M, Soret L, Angelot-Delettre F, Petrella T, Collonge-Rame MA, Seilles E, Geffroy S, Deconinck E, Daguindau E, Bouyer S, Dindinaud E, Baunin V, Le Garff-Tavernier M, Roos-Weil D, Wagner-Ballon O, Salaun V, Feuillard J, Brun S, Drenou B, Mayeur-Rousse C, Okamba P, Dorvaux V, Tichionni M, Rose J, Rubio MT, Jacob MC, Raggueneau V, Preudhomme C, Saas P, Ferrand C, Adotevi O, Roumier C, Jardin F, Garnache-Ottou F, Renosi F

Haematologica. 2020 Oct 13;Online ahead of print:

Anti-Telomerase CD4 Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV

Spehner L, Kim S, Vienot A, François E, Buecher B, Adotevi O, Vernerey D, Abdeljaoued S, Meurisse A, Borg C

Int J Mol Sci. 2020 Sep 17;21(18):

Radiotherapy Scheme Effect on PD-L1 Expression for Locally Advanced Rectal Cancer.

Boustani J, Derangère V, Bertaut A, Adotevi O, Morgand V, Charon-Barra C, Ghiringhelli F, Mirjolet C

Cells. 2020 Sep 10;9(9):

Characterization of chronic obstructive pulmonary disease in dairy farmers.

Soumagne T, Degano B, Guillien A, Annesi-Maesano I, Andujar P, Hue S, Adotevi O, Jouneau S, Botebol M, Laplante JJ, Roche N, Dalphin JC

Environ. Res.. 2020 Sep;188:109847

Molecular description of ANGPT2 associated colorectal carcinoma.

Jary M, Hasanova R, Vienot A, Asgarov K, Loyon R, Tirole C, Bouard A, Orillard E, Klajer E, Kim S, Viot J, Colle E, Adotevi O, Bouché O, Lecomte T, Borg C, Feugeas JP

Int. J. Cancer. 2020 Mar 29;:

CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm.

Bôle-Richard E, Fredon M, Biichlé S, Anna F, Certoux JM, Renosi F, Tsé F, Molimard C, Valmary-Degano S, Jenvrin A, Warda W, Pallandre JR, Bonnefoy F, Poussard M, Deschamps M, Petrella T, Roumier C, Macintyre E, Féger F, Brissot E, Mohty M, HoWangYin KY, Langlade-Demoyen P, Loustau M, Caumartin J, Godet Y, Binda D, Pagadoy M, Deconinck E, Daguindau E, Saas P, Ferrand C, Angelot-Delettre F, Adotévi O, Garnache-Ottou F

Leukemia. 2020 Feb 28;:

How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?

Garnache-Ottou F, Vidal C, Biichlé S, Renosi F, Poret E, Pagadoy M, Desmarets M, Roggy A, Seilles E, Soret L, Schillinger F, Puyraimond S, Petrella T, Preudhomme C, Roumier C, MacIntyre EA, Harrivel V, Desbrosses Y, Gruson B, Geneviève F, Thepot S, Drebit Y, Leguay T, Gros FX, Lechevalier N, Saussoy P, Salaun V, Cornet E, Benseddik Z, Veyrat-Masson R, Wagner-Ballon O, Salanoubat C, Maynadié M, Guy J, Caillot D, Jacob MC, Cahn JY, Gressin R, Rose J, Quesnel B, Guerin E, Trimoreau F, Feuillard J, Gourin MP, Plesa A, Baseggio L, Arnoux I, Vey N, Blaise D, Lacroix R, Arnoulet C, Benet B, Dorvaux V, Bret C, Drenou B, Debliquis A, Latger-Cannard V, Bonmati C, Bene MC, Peterlin P, Ticchioni M, Rohrlich PS, Arnaud A, Wickenhauser S, Bardet V, Brechignac S, Papoular B, Raggueneau V, Vargaftig J, Letestu R, Lusina D, Braun T, Foissaud V, Tamburini J, Bennani H, Freynet N, Cordonnier C, Le Garff-Tavernier M, Jacques N, Maloum K, Roos-Weil D, Bouscary D, Asnafi V, Lhermitte L, Suarez F, Lengline E, Féger F, Battipaglia G, Mohty M, Bouyer S, Ghoual O, Dindinaud E, Basle C, Puyade M, Lafon C, Fest T, Roussel M, Cahu X, Bera E, Daliphard S, Jardin F, Campos L, Solly F, Guyotat D, Galoisy AC, Eischen A, Mayeur-Rousse C, Guffroy B, Recher C, Loosveld M, Garnier A, Barlogis V, Rosenthal MA, Brun S, Contentin N, Maury S, Callanan M, Lefebvre C, Maillard N, Okamba P, Ferrand C, Adotevi O, Saas P, Angelot-Delettre F, Binda D, Deconinck E

Blood Adv. 2019 Dec 23;3(24):4238-4251

Immunoregulation and Clinical Implications of ANGPT2/TIE2+ M-MDSC Signature in Non-Small Cell Lung Cancer.

Lauret Marie Joseph E, Laheurte C, Jary M, Boullerot L, Asgarov K, Gravelin E, Bouard A, Rangan L, Dosset M, Borg C, Adotévi O

Cancer Immunol Res. 2019 Dec 23;:

Metronomic cyclophosphamide induces regulatory T cells depletion and PSA specific T cells reactivation in patients with biochemical recurrent prostate cancer.

Laheurte C, Thiery-Vuillemin A, Calcagno F, Legros A, Simonin H, Boullerot L, Jacquin M, Nguyen T, Mouillet G, Borg C, Adotévi O

Int. J. Cancer. 2019 Nov 20;:

A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors.

Teixeira L, Medioni J, Garibal J, Adotévi O, Doucet L, Dragon Durey MA, Ghrieb Z, Kiladjian JJ, Brizard M, Laheurte C, Wehbe M, Pliquet E, Escande M, Defrance R, Culine S, Oudard SM, Wain-Hobson S, Doppler V, Huet T, Langlade-Demoyen P

Clin. Cancer Res.. 2019 Sep 26;:

Let us not underestimate the long-term risk of SPLC after surgical resection of NSCLC.

Leroy T, Monnet E, Guerzider S, Jacoulet P, De Bari B, Falcoz PE, Gainet-Brun M, Lahourcade J, Alfreijat F, Almotlak H, Adotevi O, Pernet D, Polio JC, Desmarets M, Woronoff AS, Westeel V

Lung Cancer. 2019 Sep 3;137:23-30

Increased Levels of Interleukin-17A Exosomes in Psoriasis.

Jacquin-Porretaz C, Cordonnier M, Nardin C, Boullerot L, Chanteloup G, Vautrot V, Adotevi O, Garrido C, Gobbo J, Aubin F

Acta Derm. Venereol.. 2019 08 22;:

CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin.

Galaine J, Turco C, Vauchy C, Royer B, Mercier-Letondal P, Queiroz L, Loyon R, Mouget V, Boidot R, Laheurte C, Lakkis Z, Jary M, Adotévi O, Borg C, Godet Y

Int. J. Cancer. 2019 Aug 9;:

Distinct prognostic value of circulating anti-telomerase CD4 Th1 immunity and exhausted PD-1/TIM-3 T cells in lung cancer.

Laheurte C, Dosset M, Vernerey D, Boullerot L, Gaugler B, Gravelin E, Kaulek V, Jacquin M, Cuche L, Eberst G, Jacoulet P, Fabre E, Le Pimpec-Barthes F, Tartour E, De Carvalho Bittencourt M, Westeel V, Adotévi O

Br. J. Cancer. 2019 Jul 30;:

High-throughput screening of human tumor-antigen specific CD4 T cells, including neo-antigen reactive T cells.

Jandus C, Costa-Nunes C, Bobisse S, Baumgaertner P, Speiser DE, Sousa Alves PM, Sandoval F, Adotévi O, Coukos G, Harari A, Cachot A, Arnaud M, Genolet R, Reith W, Protti MP, Romero P

Clin. Cancer Res.. 2019 Apr 23;:

Enhanced emergence of antibiotic-resistant pathogenic bacteria after in vitro induction with cancer chemotherapy drugs.

Meunier A, Nerich V, Fagnoni-Legat C, Richard M, Mazel D, Adotevi O, Bertrand X, Hocquet D

J. Antimicrob. Chemother.. 2019 Feb 20;:

Cancer vaccines: designing artificial synthetic long peptides to improve presentation of class I and class II T cell epitopes by dendritic cells.

Rabu C, Rangan L, Florenceau L, Fortun A, Charpentier M, Dupré E, Paolini L, Beauvillain C, Dupel E, Latouche JB, Adotevi O, Labarrière N, Lang F

Oncoimmunology. 2019 ;8(4):e1560919

Circulating NKp46 Natural Killer cells have a potential regulatory property and predict distinct survival in Non-Small Cell Lung Cancer.

Picard E, Godet Y, Laheurte C, Dosset M, Galaine J, Beziaud L, Loyon R, Boullerot L, Lauret Marie Joseph E, Spehner L, Jacquin M, Eberst G, Gaugler B, Le Pimpec-Barthes F, Fabre E, Westeel V, Caignard A, Borg C, Adotévi O

Oncoimmunology. 2019 ;8(2):e1527498

Peripheral Innate Lymphoid Cells Are Increased in First Line Metastatic Colorectal Carcinoma Patients: A Negative Correlation With Th1 Immune Responses.

Loyon R, Jary M, Salomé B, Gomez-Cadena A, Galaine J, Kroemer M, Romero P, Trabanelli S, Adotévi O, Borg C, Jandus C

Front Immunol. 2019 ;10:2121

CML hematopoietic stem cells expressing IL-1RAP can be targeted by chimeric antigen receptor (CAR)-engineered T cells.

Warda W, Larosa F, Neto Da Rocha M, Trad R, Deconinck E, Fajloun Z, Faure C, Caillot D, Moldovan M, Valmary-Degano S, Biichle S, Daguindau E, Garnache-Ottou F, Tabruyn S, Adotévi O, Deschamps M, Ferrand C

Cancer Res.. 2018 Dec 4;:

Personalized identification of tumor-associated immunogenic neoepitopes in hepatocellular carcinoma in complete remission after sorafenib treatment.

Vrecko S, Guenat D, Mercier-Letondal P, Faucheu H, Dosset M, Royer B, Galaine J, Boidot R, Kim S, Jary M, Adotévi O, Borg C, Godet Y

Oncotarget. 2018 Oct 23;9(83):35394-35407

Clinical response and pharmacodynamic assessment of INVAC-1, a DNA plasmid encoding an inactive form of human telomerase reverse transcriptase (hTERT), on immune responses, immune tolerability, tumor burden and circulating tumor DNA (ctDNA) in patients wi

Medioni J, Brizard M, Teixeira LO, Doucet L, Ghrieb Z, Angelergues A, Oudard S, Culine S, Adotevi O, Laheurte C, Dragon-Durey MA, Laurent-Puig P, Kiladjian JJ, Doppler V, Souttou B, Wain-Hobson S, Defrance R, Huet T, Langlade-Demoyen P

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii136

Rapalog combined with CCR4 antagonist improves anticancer vaccines efficacy.

Beziaud L, Boullerot L, Tran T, Mansi L, Marie-Joseph EL, Ravel P, Johannes L, Bayry J, Tartour E, Adotévi O

Int. J. Cancer. 2018 Sep 5;:

Isolation and characterization of an HLA-DRB1*04-restricted HPV16-E7 T cell receptor for cancer immunotherapy.

Mercier-Letondal P, Marton C, Deschamps M, Ferrand C, Vauchy C, Chenut C, Baguet A, Adotévi O, Borg C, Galaine J, Godet Y

Hum. Gene Ther.. 2018 Aug 23;:

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.

Kim S, François E, André T, Samalin E, Jary M, El Hajbi F, Baba-Hamed N, Pernot S, Kaminsky MC, Bouché O, Desrame J, Zoubir M, Ghiringhelli F, Parzy A, De La Fouchardiere C, Smith D, Deberne M, Spehner L, Badet N, Adotevi O, Anota A, Meurisse A, Vernerey D, Taieb J, Vendrely V, Buecher B, Borg C

Lancet Oncol.. 2018 Jul 2;:

The Human Cytomegalovirus Strain DB Activates Oncogenic Pathways in Mammary Epithelial Cells.

Kumar A, Tripathy MK, Pasquereau S, Al Moussawi F, Abbas W, Coquard L, Khan KA, Russo L, Algros MP, Valmary-Degano S, Adotevi O, Morot-Bizot S, Herbein G

EBioMedicine. 2018 Apr;30:167-183

In situ delivery of allogeneic natural killer cell (NK) combined with Cetuximab in liver metastases of gastrointestinal carcinoma: A phase I clinical trial.

Adotevi O, Godet Y, Galaine J, Lakkis Z, Idirene I, Certoux JM, Jary M, Loyon R, Laheurte C, Kim S, Dormoy A, Pouthier F, Barisien C, Fein F, Tiberghien P, Pivot X, Valmary-Degano S, Ferrand C, Morel P, Delabrousse E, Borg C

Oncoimmunology. 2018 ;7(5):e1424673

PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer.

Dosset M, Vargas TR, Lagrange A, Boidot R, Végran F, Roussey A, Chalmin F, Dondaine L, Paul C, Marie-Joseph EL, Martin F, Ryffel B, Borg C, Adotévi O, Ghiringhelli F, Apetoh L

Oncoimmunology. 2018 ;7(6):e1433981

PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma.

Asgarova A, Asgarov K, Godet Y, Peixoto P, Nadaradjane A, Boyer-Guittaut M, Galaine J, Guenat D, Mougey V, Perrard J, Pallandre JR, Bouard A, Balland J, Tirole C, Adotevi O, Hendrick E, Herfs M, Cartron PF, Borg C, Hervouet E

Oncoimmunology. 2018 ;7(5):e1423170

SALL4 oncogene is an immunogenic antigen presented in various HLA-DR contexts.

Kroemer M, Spehner L, Mercier-Letondal P, Boullerot L, Kim S, Jary M, Galaine J, Picard E, Ferrand C, Nguyen T, Larosa F, Adotévi O, Godet Y, Borg C

Oncoimmunology. 2018 ;7(4):e1412030

More on Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma.

Tiberghien P, Deconinck E, Adotevi O

N. Engl. J. Med.. 2017 11 23;377(21):2101-2

Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A0201/DRB10101 transgenic mice.

Rangan L, Galaine J, Boidot R, Hamieh M, Dosset M, Francoual J, Beziaud L, Pallandre JR, Marie Joseph EL, Asgarova A, Borg C, Saati TA, Godet Y, Latouche JB, Valmary-Degano S, Adotévi O

Oncotarget. 2017 Apr;:

Galaine J, Godet Y, Adotévi O

Bull Cancer. 2016 Nov;103 Suppl 1:S127-S131

Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological score.

Jary M, Lecomte T, Bouché O, Kim S, Dobi E, Queiroz L, Ghiringhelli F, Etienne H, Léger J, Godet Y, Balland J, Lakkis Z, Adotevi O, Bonnetain F, Borg C, Vernerey D

Int. J. Cancer. 2016 Nov;139(10):2325-35

Heparan Sulfate Proteoglycans Promote Telomerase Internalization and MHC Class II Presentation on Dendritic Cells.

Galaine J, Kellermann G, Guillaume Y, Boidot R, Picard E, Loyon R, Queiroz L, Boullerot L, Beziaud L, Jary M, Mansi L, André C, Lethier L, Ségal-Bendirdjian E, Borg C, Godet Y, Adotévi O

J. Immunol.. 2016 Sep;197(5):1597-608

Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial.

Calcagno F, Mouillet G, Adotevi O, Maurina T, Nguyen T, Montcuquet P, Curtit E, Kleinclauss F, Pivot X, Borg C, Thiery-Vuillemin A

Med. Oncol.. 2016 Aug;33(8):89

IL-21-Induced MHC Class II+ NK Cells Promote the Expansion of Human Uncommitted CD4+ Central Memory T Cells in a Macrophage Migration Inhibitory Factor-Dependent Manner.

Loyon R, Picard E, Mauvais O, Queiroz L, Mougey V, Pallandre JR, Galaine J, Mercier-Letondal P, Kellerman G, Chaput N, Wijdenes J, Adotévi O, Ferrand C, Romero P, Godet Y, Borg C

J. Immunol.. 2016 Jul;197(1):85-96

Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity.

Beziaud L, Mansi L, Ravel P, Marie-Joseph EL, Laheurte C, Rangan L, Bonnefoy F, Pallandre JR, Boullerot L, Gamonet C, Vrecko S, Queiroz L, Maurina T, Mouillet G, Hon TN, Curtit E, Royer B, Gaugler B, Bayry J, Tartour E, Thiery-Vuillemin A, Pivot X, Borg C, Godet Y, Adotévi O

Cancer Res.. 2016 Jul;76(14):4100-12

Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4(+) Th1 responses against telomerase in cancer patients.

Laheurte C, Galaine J, Beziaud L, Dosset M, Kerzerho J, Jacquemard C, Gaugler B, Ferrand C, Dormoy A, Aubin F, Jacoulet P, Westeel V, Borg C, Tartour E, Godet Y, Maillère B, Adotévi O

Oncoimmunology. 2016 May;5(5):e1137416

CD20 alternative splicing isoform generates immunogenic CD4 helper T epitopes.

Vauchy C, Gamonet C, Ferrand C, Daguindau E, Galaine J, Beziaud L, Chauchet A, Henry Dunand CJ, Deschamps M, Rohrlich PS, Borg C, Adotevi O, Godet Y

Int J Cancer. 2015 Jul 1;137(1):116-26

Interest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer Vaccine.

Galaine J, Borg C, Godet Y, Adotevi O

Vaccines (Basel). 2015 Jun 30;3(3):490-502

Prognostic Value of Angiopoietin-2 for death risk stratification in Patients with Metastatic Colorectal Carcinoma.

Jary M, Vernerey D, Lecomte T, Dobi E, Ghiringhelli F, Monnien F, Godet Y, Kim S, Bouche O, Fratte S, Goncalves A, Leger J, Queiroz L, Adotevi O, Bonnetain F, Borg C

Cancer Epidemiol Biomarkers Prev. 2015 Jan 12. pii: cebp.1059.2014.

Immunogenicity evaluation of a rationally designed polytope construct encoding HLA-A*0201 restricted epitopes derived from Leishmania major related proteins in HLA-A2/DR1 transgenic mice: steps toward polytope vaccine.

Seyed N, Taheri T, Vauchy C, Dosset M, Godet Y, Eslamifar A, Sharifi I, Adotevi O, Borg C, Rohrlich PS, Rafati S

PLoS One. 2014 Oct 13;9(10):e108848

Immunomodulatory effects of everolimus in a long responsive patient with metastatic renal cell carcinoma.

Thiery-Vuillemin A, Laheurte C, Mansi L, Royer B, Pivot X, Borg C, Adotevi O

J Immunother. 2014 Jan;37(1):51-4

Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine.

Adotevi O, Dosset M, Galaine J, Beziaud L, Godet Y, Borg C

Hum Vaccin Immunother. 2013 May;9(5):1073-7

Impact of STAT3 phosphorylation on the clinical effectiveness of anti-EGFR-based therapy in patients with metastatic colorectal cancer.

Dobi E, Monnien F, Kim S, Ivanaj A, N'Guyen T, Demarchi M, Adotevi O, Thierry-Vuillemin A, Jary M, Kantelip B, Pivot X, Godet Y, Degano SV, Borg C

Clin Colorectal Cancer. 2013 Mar;12(1):28-36

Universal tumor-reactive helper peptides from telomerase as new tools for anticancer vaccination.

Dosset M, Vauchy C, Beziaud L, Adotevi O, Godet Y

Oncoimmunology. 2013 Mar 1;2(3):e23430.

Is preexisting antitumor CD4 T cell response indispensable for the chemotherapy induced immune regression of cancer?

Godet Y, Dosset M, Borg C, Adotevi O

Oncoimmunology. 2012 Dec 1;1(9):1617-1619.

Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor.

Dosset M, Godet Y, Vauchy C, Beziaud L, Lone YC, Sedlik C, Liard C, Levionnois E, Clerc B, Sandoval F, Daguindau E, Wain-Hobson S, Tartour E, Langlade-Demoyen P, Borg C, Adotevi O

Clin Cancer Res. 2012 Nov 15;18(22):6284-95

[Immunotherapy: an emerging strategies against prostate castration resistant cancer].

Mansi L, Thiery-Vuillemin A, Kalbacher E, Nguyen T, Maurina T, Nallet J, Kim S, Borg C, Kleinclauss F, Pivot X, Adotevi O

Bull Cancer. 2012 Jul;99 Suppl 1:S57-65

Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response.

Godet Y, Fabre E, Dosset M, Lamuraglia M, Levionnois E, Ravel P, Benhamouda N, Cazes A, Le Pimpec-Barthes F, Gaugler B, Langlade-Demoyen P, Pivot X, Saas P, Maillere B, Tartour E, Borg C, Adotevi O

Clin Cancer Res. 2012 May 15;18(10):2943-53

Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer.

Pere H, Tanchot C, Bayry J, Terme M, Taieb J, Badoual C, Adotevi O, Merillon N, Marcheteau E, Quillien VR, Banissi C, Carpentier A, Sandoval F, Nizard M, Quintin-Colonna F, Kroemer G, Fridman WH, Zitvogel L, Oudard SP, Tartour E

Oncoimmunology. 2012 May;1(3):326-333

A CCR4 antagonist combined with vaccines induces antigen-specific CD8+ T cells and tumor immunity against self antigens.

Pere H, Montier Y, Bayry J, Quintin-Colonna F, Merillon N, Dransart E, Badoual C, Gey A, Ravel P, Marcheteau E, Batteux F, Sandoval F, Adotevi O, Chiu C, Garcia S, Tanchot C, Lone YC, Ferreira LC, Nelson BH, Hanahan D, Fridman WH, Johannes L, Tartour E

Blood. 2011 Nov;118(18):4853-62

A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients.

Adotevi O, Pere H, Ravel P, Haicheur N, Badoual C, Merillon N, Medioni J, Peyrard S, Roncelin S, Verkarre V, Mejean A, Fridman WH, Oudard S, Tartour E

J Immunother. 2010 Nov-Dec;33(9):991-8.

Immunogenicity of a recombinant lentiviral vector carrying human telomerase tumor antigen in HLA-B*0702 transgenic mice.

Rusakiewicz S, Dosset M, Mollier K, Souque P, Charneau P, Wain-Hobson S, Langlade-Demoyen P, Adotevi O

Vaccine. 2010 Aug 31;28(38):6374-81

The angiogenic growth factor and biomarker midkine is a tumor-shared antigen.

Kerzerho J, Adotevi O, Castelli FA, Dosset M, Bernardeau K, Szely N, Lang F, Tartour E, Maillere B

J Immunol. 2010 Jul 1;185(1):418-23

Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo.

Adotevi O, Mollier K, Neuveut C, Dosset M, Ravel P, Fridman WH, Tartour E, Charneau P, Wain-Hobson S, Langlade-Demoyen P

Blood. 2010 Apr 15;115(15):3025-32

Comprehensive analysis of HLA-DR- and HLA-DP4-restricted CD4+ T cell response specific for the tumor-shared antigen survivin in healthy donors and cancer patients.

Wang XF, Kerzerho J, Adotevi O, Nuyttens H, Badoual C, Munier G, Oudard S, Tu S, Tartour E, Maillere B

J Immunol. 2008 Jul 1;181(1):431-9.

Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients

Bercovici N, Haicheur N, Massicard S, Vernel-Pauillac F, Adotevi O, Landais D, Gorin I, Robert C, Prince HM, Grob JJ, Leccia MT, Lesimple T, Wijdenes J, Bartholeyns J, Fridman WH, Salcedo M, Ferries E, Tartour E

J Immunother. 2008 Jan;31(1):101-12.

B subunit of Shiga toxin-based vaccines synergize with alpha-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity.

Adotevi O, Vingert B, Freyburger L, Shrikant P, Lone YC, Quintin-Colonna F, Haicheur N, Amessou M, Herbelin A, Langlade-Demoyen P, Fridman WH, Lemonnier F, Johannes L, Tartour E

J Immunol. 2007 Sep 1;179(5):3371-9.

Lentiviral vectors encoding HIV-1 polyepitopes induce broad CTL responses in vivo.

Iglesias MC, Mollier K, Beignon AS, Souque P, Adotevi O, Lemonnier F, Charneau P

Mol Ther. 2007 Jun;15(6):1203-10

Immunogenic HLA-B7-restricted peptides of hTRT.

Cortez-Gonzalez X, Sidney J, Adotevi O, Sette A, Millard F, Lemonnier F, Langlade-Demoyen P, Zanetti M

Int Immunol. 2006 Dec;18(12):1707-18

Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.

Adotevi O, Mollier K, Neuveut C, Cardinaud S, Boulanger E, Mignen B, Fridman WH, Zanetti M, Charneau P, Tartour E, Lemonnier F, Langlade-Demoyen P

Clin Cancer Res. 2006 May 15;12(10):3158-67.

The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens.

Haicheur N, Bismuth E, Bosset S, Adotevi O, Warnier G, Lacabanne V, Regnault A, Desaymard C, Amigorena S, Ricciardi-Castagnoli P, Goud B, Fridman WH, Johannes L, Tartour E

J Immunol. 2000 Sep 15;165(6):3301-8.

Fiche personne Projets Publications

Retrouvez aussi

Personnes

Equipes

Plateformes

Unités de recherche, établissements

Projets de recherche

Publications scientifiques